title: Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.
abstract: Despite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies, relapse remains the leading cause of death after transplant. Biologic and clinical investigations are needed to combat this primary cause of death after transplantation. The National Cancer Institute held international workshops in 2009 and 2012 to help address this problem. Three major initiatives for coordinated research were proposed: 1) To establish multicenter networks for basic, translational, epidemiologic and clinical research; 2) To establish a network of biorepositories for the collection of samples before and after HSCT to aid in laboratory and clinical studies; and 3) To refine, implement and study proposed definitions for disease-specific response and relapse and for monitoring of minimal residual disease. The workshop in 2012 also featured nine presentations, summaries of which follow in three manuscripts.
authors.affiliation: Children's Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, The Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California; Organizing Committee, National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation. Electronic address: awayne@chla.usc.edu.
authors.forename: Alan S
authors.initials: AS
authors.lastname: Wayne
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bishop
mesh_terms: D019337:Hematologic Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D054547:National Cancer Institute (U.S.); D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000628:therapy; D019172:Transplantation Conditioning / Q000379:methods; D014481:United States
keywords: Allogeneic; Autologous; Hematologic malignancies; Hematopoietic stem cell transplantation; Post-transplant relapse
references.citation: Biol Blood Marrow Transplant. 2010 Sep;16(9):1187-211
references.pmid: 20558311
references.citation: Leukemia. 2011 Jan;25(1):181-4
references.pmid: 20944674
references.citation: Leukemia. 2013 Jun;27(6):1229-35
references.pmid: 23314834
references.citation: Biol Blood Marrow Transplant. 2010 Nov;16(11):1467-503
references.pmid: 20699125
references.citation: Biol Blood Marrow Transplant. 2010 Jul;16(7):871-90
references.pmid: 20399876
references.citation: Biol Blood Marrow Transplant. 2010 Oct;16(10):1325-46
references.pmid: 20637879
references.citation: N Engl J Med. 2012 Mar 22;366(12):1090-8
references.pmid: 22417201
references.citation: Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69
references.pmid: 20580849
references.citation: N Engl J Med. 2012 May 10;366(19):1770-81
references.pmid: 22571201
references.citation: Biol Blood Marrow Transplant. 2011 Apr;17(4):443-54
references.pmid: 21224011
references.citation: Biol Blood Marrow Transplant. 2010 May;16(5):563-4
references.pmid: 20202482
references.citation: Nature. 2012 Jan 11;481(7382):506-10
references.pmid: 22237025
references.citation: N Engl J Med. 2012 May 10;366(19):1782-91
references.pmid: 22571202
references.citation: Cancer. 2010 Dec 1;116(23):5420-31
references.pmid: 20672358
references.citation: Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28
references.pmid: 20227509
references.citation: Biol Blood Marrow Transplant. 2010 May;16(5):565-86
references.pmid: 20152921